The following information is provided by Tiziana Life Sciences LTD (the "Company").

Tiziana Life Sciences LTD (“Company”) is a biotechnology company that focuses on developing alternative routes of immunotherapies with innovative drugs for neurodegenerative and gastrointestinal diseases. Our major focuses are nasal immunotherapy for Secondary Progressive Multiple Sclerosis, oral immunotherapy for Crohn's Disease and inhalation therapy for lung diseases. On 24 April 2014 the Company acquired Tiziana Pharma Limited (“TPL”) via a reverse takeover. TPL was formed in November 2013 as a vehicle to acquire and exploit certain intellectual property in biotechnology.

On 22 December 2014, the Company in-licensed the molecule foralumab, the only fully human engineered anti-human CD3 antibody in clinical development, from Novimmune SA. Foralumab targets the CD3 epsilon (CD3ε) receptor, which is a recognised approach for modulating T-Cell response and achieving immunosuppression. Foralumab has potential application in a wide range of neurodegenerative diseases, such as secondary progressive multiple sclerosis. Tiziana has recently submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival.

On 20 January 2015, the Company in-licensed milciclib from Nerviano Medical Sciences. The compound milciclib blocks the action of a specific set of enzymes known as cyclin-dependent kinases (CDKs), which are involved in the process of cell division, as well as a number of other protein kinases. Milciclib has an unusual kinase inhibitory profile making it active against other receptors such as, tyrosine kinase, src family and splicing kinases. Milciclib has demonstrated safety and tolerability in 316 patients with advanced solid cancers in Phase 1 and 2 studies and also exhibited positive clinical responses. In two, successfully completed, Phase 2 thymic cancer trials, Milciclib successfully increased overall survival and met both primary and secondary endpoints. Clinical data from a Phase I dose-escalation study with combination of milciclib with gemcitabine showed significant disease stabilization and suggested that milciclib can reverse gemcitabine-resistance in NSCLC refractory solid tumors.

In March 2020 Tiziana announced that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb). Tiziana plans to administer TZLS-501 as an aerosol directly to the site of inflammation using a hand held nebulizer. The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017.

For more information please see “About Us”.